Alec Stranahan
Stock Analyst at Bank of America Securities
(4.09)
# 1,191
Out of 4,668 analysts
631
Total ratings
52.5%
Success rate
5.4%
Average return
Main Sectors:
Stocks Rated by Alec Stranahan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PRQR ProQR Therapeutics | Initiated Coverage: Buy | $8 | $2.27 | +252.42% | 1 | Aug 20, 2026 | |
| MRNA Moderna | Upgraded: Hold | $40 → $170 | $133.32 | +27.51% | 26 | Aug 19, 2026 | |
| IMTX Immatics | Reiterated: Buy | $17 | $8.55 | +98.83% | 18 | Aug 18, 2026 | |
| CATX Perspective Therapeutics | Reiterated: Hold | $6 → $5 | $3.21 | +55.76% | 18 | Aug 14, 2026 | |
| MGTX MeiraGTx Holdings | Reiterated: Buy | $19 | $14.54 | +30.67% | 17 | Aug 14, 2026 | |
| SANA Sana Biotechnology | Reiterated: Buy | $7 → $6 | $3.74 | +60.43% | 13 | Aug 14, 2026 | |
| ERAS Erasca | Rated: Hold | $18 → $20 | $17.08 | +17.10% | 27 | Aug 14, 2026 | |
| CRBU Caribou Biosciences | Maintained: Buy | $6 → $5 | $1.61 | +210.56% | 16 | Aug 14, 2026 | |
| CADL Candel Therapeutics | Reiterated: Hold | $9 → $12 | $12.35 | -2.83% | 18 | Aug 14, 2026 | |
| AKTS Aktis Oncology | Maintained: Buy | $34 | $24.00 | +41.67% | 9 | Aug 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $17 | $5.25 | +223.81% | 7 | Aug 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $6 | $3.34 | +79.64% | 24 | Aug 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Sell | $8 → $7 | $8.42 | -16.86% | 42 | Aug 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $17 → $20 | $27.00 | -25.93% | 19 | Aug 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $14 → $15 | $11.06 | +35.62% | 28 | Aug 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Sell | n/a | $2.94 | - | 10 | Aug 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $19 → $17 | $12.44 | +36.66% | 19 | Aug 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $35 | $19.82 | +76.59% | 2 | Aug 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Sell | $1 | $2.26 | -55.75% | 16 | Aug 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $16 → $15 | $9.21 | +62.87% | 21 | Aug 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $21 → $22 | $17.28 | +27.31% | 22 | Aug 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $87 → $88 | $77.61 | +13.39% | 19 | Aug 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $212 → $225 | $211.74 | +6.26% | 36 | Aug 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Sell | $20 → $21 | $50.56 | -58.47% | 38 | Aug 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $83 → $82 | $58.12 | +41.09% | 27 | Aug 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $47 → $43 | $28.39 | +51.46% | 24 | Aug 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $396 → $392 | $337.02 | +16.31% | 32 | Aug 3, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $17 → $16 | $12.56 | +27.39% | 23 | Jul 31, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $46 | $33.63 | +36.78% | 34 | Jul 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Sell | $1 | $0.7985 | +25.23% | 13 | Mar 27, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Sell | $800 → $565 | $826.64 | n/a | 3 | Dec 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $1,150 → $1,100 | $1,244.40 | n/a | 3 | Nov 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $6 → $5 | $30.31 | n/a | 2 | Aug 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Sell | $10 → $1 | $6.25 | n/a | 4 | Dec 2, 2022 |
ProQR Therapeutics
Aug 20, 2026
Initiated Coverage: Buy
Price Target: $8
Current: $2.27
Upside: +252.42%
Moderna
Aug 19, 2026
Upgraded: Hold
Price Target: $40 → $170
Current: $133.32
Upside: +27.51%
Immatics
Aug 18, 2026
Reiterated: Buy
Price Target: $17
Current: $8.55
Upside: +98.83%
Perspective Therapeutics
Aug 14, 2026
Reiterated: Hold
Price Target: $6 → $5
Current: $3.21
Upside: +55.76%
MeiraGTx Holdings
Aug 14, 2026
Reiterated: Buy
Price Target: $19
Current: $14.54
Upside: +30.67%
Sana Biotechnology
Aug 14, 2026
Reiterated: Buy
Price Target: $7 → $6
Current: $3.74
Upside: +60.43%
Erasca
Aug 14, 2026
Rated: Hold
Price Target: $18 → $20
Current: $17.08
Upside: +17.10%
Caribou Biosciences
Aug 14, 2026
Maintained: Buy
Price Target: $6 → $5
Current: $1.61
Upside: +210.56%
Candel Therapeutics
Aug 14, 2026
Reiterated: Hold
Price Target: $9 → $12
Current: $12.35
Upside: -2.83%
Aktis Oncology
Aug 14, 2026
Maintained: Buy
Price Target: $34
Current: $24.00
Upside: +41.67%
Aug 12, 2026
Maintained: Buy
Price Target: $17
Current: $5.25
Upside: +223.81%
Aug 12, 2026
Maintained: Hold
Price Target: $6
Current: $3.34
Upside: +79.64%
Aug 7, 2026
Reiterated: Sell
Price Target: $8 → $7
Current: $8.42
Upside: -16.86%
Aug 7, 2026
Reiterated: Hold
Price Target: $17 → $20
Current: $27.00
Upside: -25.93%
Aug 7, 2026
Reiterated: Buy
Price Target: $14 → $15
Current: $11.06
Upside: +35.62%
Aug 7, 2026
Reiterated: Sell
Price Target: n/a
Current: $2.94
Upside: -
Aug 7, 2026
Reiterated: Hold
Price Target: $19 → $17
Current: $12.44
Upside: +36.66%
Aug 7, 2026
Reiterated: Buy
Price Target: $35
Current: $19.82
Upside: +76.59%
Aug 7, 2026
Reiterated: Sell
Price Target: $1
Current: $2.26
Upside: -55.75%
Aug 7, 2026
Reiterated: Buy
Price Target: $16 → $15
Current: $9.21
Upside: +62.87%
Aug 7, 2026
Reiterated: Buy
Price Target: $21 → $22
Current: $17.28
Upside: +27.31%
Aug 7, 2026
Reiterated: Buy
Price Target: $87 → $88
Current: $77.61
Upside: +13.39%
Aug 6, 2026
Maintained: Buy
Price Target: $212 → $225
Current: $211.74
Upside: +6.26%
Aug 5, 2026
Reiterated: Sell
Price Target: $20 → $21
Current: $50.56
Upside: -58.47%
Aug 5, 2026
Reiterated: Buy
Price Target: $83 → $82
Current: $58.12
Upside: +41.09%
Aug 5, 2026
Reiterated: Buy
Price Target: $47 → $43
Current: $28.39
Upside: +51.46%
Aug 3, 2026
Reiterated: Buy
Price Target: $396 → $392
Current: $337.02
Upside: +16.31%
Jul 31, 2026
Maintained: Buy
Price Target: $17 → $16
Current: $12.56
Upside: +27.39%
Jul 30, 2026
Reiterated: Buy
Price Target: $46
Current: $33.63
Upside: +36.78%
Mar 27, 2026
Reiterated: Sell
Price Target: $1
Current: $0.7985
Upside: +25.23%
Dec 10, 2024
Initiated Coverage: Sell
Price Target: $800 → $565
Current: $826.64
Upside: n/a
Nov 1, 2024
Rated: Buy
Price Target: $1,150 → $1,100
Current: $1,244.40
Upside: n/a
Aug 15, 2023
Reiterated: Buy
Price Target: $6 → $5
Current: $30.31
Upside: n/a
Dec 2, 2022
Maintained: Sell
Price Target: $10 → $1
Current: $6.25
Upside: n/a